

## Amendments to the Claims

Claim 1 (currently amended): A method for capture of one or more antibodies from a liquid, ~~which method comprises~~ comprising contacting said liquid with a chromatography resin ~~comprised of~~ including a support to which multi-modal ligands have been immobilised to adsorb the antibodies to the resin, wherein each multi-modal ligand ~~comprises~~ includes at least one cation-exchanging group and at least one aromatic or heteroaromatic ring system, in which system the ring-forming atoms are selected from the group consisting of carbon (C), sulphur (S) and oxygen (O) atoms.

Claim 2 (currently amended): ~~A method according to~~ The method of claim 1, wherein the ring-forming atoms are selected from the group consisting of carbon (C) and sulphur (S) atoms.

Claim 3 (currently amended): ~~A method according to~~ The method of claim 2, wherein the ring-forming atoms are carbon (C) atoms.

Claim 4 (currently amended): ~~A method according to any one of claims 1-3,~~ The method of claim 1, which is followed by one or further purification steps.

Claim 5 (currently amended): A process for the purification of one or more antibodies from a liquid, ~~which process comprises~~ comprising contacting said liquid with a first chromatography resin ~~comprised of~~ including a support to which multi-modal ligands have been immobilised to adsorb the antibodies to the resin, wherein each multi-modal ligand ~~comprises~~ includes at least one cation-exchanging group and at least one

aromatic or heteroaromatic ring system; adding an eluent to release the antibodies from the resin; and contacting the eluate so obtained with a second chromatography resin.

Claim 6 (currently amended): ~~A process according to any one of the preceding claims,~~  
The process of claim 5, wherein the liquid contacted with the multi-modal chromatography resin is a cell culture liquid or a fermentation broth.

Claim 7 (currently amended): ~~A process according to claim 5 or 6,~~ The process of claim 5, wherein the ring-forming atoms of the aromatic or heteroaromatic ring system of the multi-modal ligands are selected from the group consisting of carbon (C), sulphur (S) and oxygen (O) atoms.

Claim 8 (currently amended): ~~A process according to any one of the preceding claims,~~  
The process of claim 5, wherein the cation-exchanging group of the multi-modal ligands is a weak cation exchanger.

Claim 9 (currently amended): ~~A process according to any one of the preceding claims,~~  
The process of claim 5, wherein the second chromatography step is selected from the group ~~that consists~~ consisting of ion exchange chromatography; hydrophobic interaction chromatography (HIC); immobilised metal affinity chromatography (IMAC); and affinity chromatography.

Claim 10 (currently amended): ~~A process according to~~ The process of claim 9, wherein the second chromatography step is ion exchange chromatography.

Claim 11 (currently amended): ~~A process according to any one of the preceding claims,~~ The process of claim 5, wherein the second chromatography step is anion exchange chromatography.

Claim 12 (currently amended): ~~A process according any one of the preceding claims,~~ The process of claim 5, wherein the second chromatography step is multimodal anion exchange chromatography.

Claim 13 (currently amended): ~~A process according to any one of the preceding claims,~~ The process of claim 5, wherein antibodies are recovered from the flow-through of the second chromatography resin.

Claim 14 (currently amended): ~~A process according to any one of claims 1-12,~~ The process of claim 5, wherein antibodies and/or impurities are eluted from the second chromatography resin.

Claim 15 (currently amended): ~~A process according to any one of the preceding claims,~~ The process of claim 5, wherein the antibodies are monoclonal antibodies.

Claim 16 (currently amended): ~~A process according to any one of claims 1-14,~~ The process of claim 5, wherein the antibodies are polyclonal antibodies.

Claim 17 (currently amended): A method for capture of one or more antibodies from a liquid, ~~which process comprises~~ comprising contacting said liquid with a

chromatography resin to adsorb the antibodies to the ligands, which resin is multimodal and comprises a support to which ligands have been immobilised, wherein the resin ~~comprises~~ includes cation-exchanging groups and aromatic or heteroaromatic ring systems present on the same or different ligands, in which systems the ring-forming atoms are selected from the group consisting of carbon (C), sulphur (S) and oxygen (O) atoms.

Claim 18 (currently amended): A process for the purification of one or more antibodies from a liquid, ~~which process comprises~~ comprising contacting said liquid with a first chromatography resin to adsorb the antibodies to the ligands, which resin is multimodal and comprises a support to which ligands have been immobilised, wherein the resin ~~comprises~~ includes cation-exchanging groups and aromatic or heteroaromatic ring systems present on the same or different ligands; adding an eluent to release the antibodies from the resin; and contacting the eluate so obtained with a second chromatography resin.

Claim 19 (currently amended): A kit for the purification of one or more antibodies in a liquid, ~~which kit comprises~~ comprising in separate compartments a first chromatography column packed with a chromatography resin, which resin is multimodal and ~~comprises~~ includes a support to which ligands have been immobilised, wherein cation-exchanging groups and aromatic or heteroaromatic ring systems are present on the same or different ligands; a second chromatography column packed with a chromatography resin; one or more buffers for adsorption and or elution of antibodies; and written instructions that teaches the purification of antibodies in a two-step process.

Claim 20 (currently amended): ~~A kit according to~~ The kit of claim 19, wherein the ring-forming atoms of the aromatic or heteroaromatic ring system of the multi-modal ligands are selected from the group consisting of carbon (C), sulphur (S) and oxygen (O) atoms.

Claim 21 (currently amended): ~~A kit according to~~ The kit of claim 19 or 20, wherein the first chromatography column is a sterile column.

Claim 22 (currently amended): ~~A kit according to any one of claims 19-21,~~ The kit of claim 19, wherein the first chromatography column is a disposable column.

Claim 23 (currently amended): A disposable chromatography column for the purification of antibodies, ~~which column comprises~~ comprising a multi-modal chromatography resin comprising cation-exchanging groups and aromatic and/or heteroaromatic ring systems on the same or different ligands.

Claim 24 (currently amended): A disposable chromatography column for the purification of antibodies, ~~which column comprises~~ comprising a multi-modal chromatography resin, wherein each ligand comprises at least one cation-exchanging group and at least one aromatic or heteroaromatic ring system.

Claim 25 (currently amended): ~~A disposable column according to claim 23 or 24,~~ The disposable column of claim 23, wherein the ring-forming atoms of the aromatic or

heteroaromatic ring system of the multi-modal ligands are selected from the group consisting of carbon (C), sulphur (S) and oxygen (O) atoms.

Claim 26 (new): The method of claim 1, wherein the liquid contacted with the multi-modal chromatography resin is a cell culture liquid or a fermentation broth.

Claim 27 (new): The method of claim 1, wherein the cation-exchanging group of the multi-modal ligands is a weak cation exchanger.

Claim 28 (new): The method of claim 1, wherein the antibodies are monoclonal antibodies.

Claim 29 (new): The method of claim 1, wherein the antibodies are polyclonal antibodies.

Claim 30 (new): The disposable column of claim 24, wherein the ring-forming atoms of the aromatic or heteroaromatic ring system of the multi-modal ligands are selected from the group consisting of carbon (C), sulphur (S) and oxygen (O) atoms.